The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704
Open accessAbstract
Purpose: CA 19-9 is an important tumor marker in patients with pancreatic adenocarcinoma. A secondary end point of Radiation Therapy Oncology Group trial 9704 was prospective evaluation of the ability of postresectional CA 19-9 to predict survival. Methods: CA 19-9 expression was analyzed as a dichotomized variable (< 180 v ≥ 180) or (≤ 90 v > 90). Cox proportional hazards models were utilized to identify the impact of CA 19-9 expression on overall survival (OS). Actuarial estimates for OS were calculated using Kaplan-Meier methods. Results: Three hundred eighty-five patients patients had assessable CA 19-9 levels. The majority had a CA 19-9 level lower than 180 or ≤ 90 (n = 220 and 200, respectively), while 34% were Lewis Antigen negative and 33 (9%) and 53 (14%) patients had levels higher than 180 and higher than 90. When CA 19-9 was analyzed as a dichotomized variable, there was a significant survival difference favoring patients with CA 19-9 lower than 180 (hazard ratio [HR], 3.53; P < .0001). This corresponds to a 72% reduction in the risk of death for patients with a CA 19-9 lower than 180. This was also true for patients with CA 19-9 ≤ 90 (HR, 3.4; P < .0001). Multivariate analyses confirmed that CA 19-9, when analyzed as both a continuous and a dichotomized variable, is a highly significant predictor of OS in patients with resected pancreatic cancer. Conclusion: To our knowledge, this is the first phase III trial to perform prospective analysis of CA 19-9 levels in patients treated with adjuvant chemoradiotherapy. It definitively confirms the prognostic importance of postresectional CA 19-9 levels after surgery with curative intent in patients with pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Pancreatic Cancer: Adjuvant Combined Radiation and Chemotherapy Following Curative Resection
Kaiser, M. H. (1985) · Archives of Surgery · doi:10.1001/archsurg.1985.01390320023003 · Cited by 1,406
Colorectal carcinoma antigens detected by hybridoma antibodies
Koprowski, H., Steplewski, Z., Mitchell, K., Herlyn, M., Herlyn, D., & Fuhrer, P. (1979) · Somatic Cell Genetics · doi:10.1007/bf01542654 · Cited by 1,364
Klinkenbijl, J. H., Jeekel, J., Sahmoud, T., van Pel, R., Couvreur, M. L., Veenhof, C. H., Arnaud, J. P., Gonzalez, D. G., de Wit, L. T., Hennipman, A., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199912000-00006 · Cited by 1,286
Neoptolemos, J., Dunn, J., Stocken, D., Almond, J., Link, K., Beger, H., Bassi, C., Falconi, M., Pederzoli, P., Dervenis, C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06651-x · Cited by 1,111
Magnani, J. L., Nilsson, B., Brockhaus, M., Zopf, D., Steplewski, Z., Koprowski, H., & Ginsburg, V (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)45389-1 · Cited by 881
Regine, W. F., Winter, K. A., Abrams, R. A., Safran, H., Hoffman, J. P., Konski, A., Benson, A. B., Macdonald, J. S., Kudrimoti, M. R., Fromm, M. L., et al. (2008) · JAMA · doi:10.1001/jama.299.9.1019 · Cited by 755
Self-citationFerrone, C. R., Finkelstein, D. M., Thayer, S. P., Muzikansky, A., Castillo, C. F.-D., & Warshaw, A. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3934 · Cited by 554
Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.
Tempero, M. A., Uchida, E., Takasaki, H., Burnett, D. A., Steplewski, Z., & Pour, P. M. (1987) · PubMed · Cited by 400
Role of tumour markers, cytogenetics
Lamerz, R. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_4.s145 · Cited by 178
Glenn, J. D., Steinberg, W. M., Kurtzman, S. H., Steinberg, S. M., & Sindelar, W. F. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.3.462 · Cited by 139
Berger, A. C., Meszoely, I. M., Ross, E. A., Watson, J. C., & Hoffman, J. P. (2004) · Annals of Surgical Oncology · doi:10.1245/aso.2004.11.025 · Cited by 133
Self-citationMontgomery, R. C., Hoffman, J. P., Riley, L. B., Rogatko, A., Ridge, J. A., & Eisenberg, B. L. (1997) · Annals of Surgical Oncology · doi:10.1007/bf02305535 · Cited by 128
Self-citation
Cited by
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Neoptolemos, J. P., Stocken, D. D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M. J., Gallinger, S., Mariette, C., et al. (2010) · JAMA · doi:10.1001/jama.2010.1275 · Cited by 1,397
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 489
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer
Patra, C. R., Bhattacharya, R., Mukhopadhyay, D., & Mukherjee, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.007 · Cited by 458
The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates
E. Poruk, K., Z. Gay, D., Brown, K., D. Mulvihill, J., M. Boucher, K., L. Scaife, C., A. Firpo, M., & J. Mulvihill, S. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313030003 · Cited by 398
Metadata
- Authors
- Berger, A. C., Garcia, M., Hoffman, J. P., Regine, W. F., Abrams, R. A., Safran, H., Konski, A., Benson, A. B., MacDonald, J., & Willett, C. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-12-20
- Volume
- 26
- Issue
- 36
- Pages
- 5918-5922
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131204916
- Cited by
- 371
- References
- 18
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.